Clinical Medicine Reviews in Vascular Health

Alogliptin benzoate is a DPP-4 inhibitor currently in Phase 3 clinical trials in the United States for treatment of T2DM. Alogliptin is approved and available for use in Japan for the treatment of T2DM. Alogliptin has been studied clinically as initial therapy in treatment naïve patients with T2DM, as initial therapy in combination with pioglitazone, and as add-on therapy to T2DM patients with inadequate control on metformin, glyburide, pioglitazone, and insulin. Clinical trial data with alogliptin demonstrate clinical efficacy in terms of A1C and FPG reductions when used both as monotherapy and in combination with other oral antidiabetic medications. Overall, alogliptin is generally well tolerated when used as monotherapy and in combination with concomitant oral antidiabetic therapy. Comparative studies are needed to determine the clinical advantages, if any, of alogliptin when compared with other currently available DPP-4 inhibitors.